高通量血液透析治疗终末期肾衰竭的效果分析  

Effect of high-flux hemodialysis in the treatment of patients with end-stage renal failure

作　　者：黄培华[1] 黄华[1] 桓文穆[1] 林紫云[1] 郭泽慧[1] 

机构地区：[1]广东药学院附属第一医院,510080

出　　处：《首都食品与医药》2016年第14期45-46,共2页Capital Food Medicine

摘　　要：目的观察高通量血液透析治疗终末期肾衰竭的效果。方法选取我院住院治疗的65例终末期肾衰竭患者,随机将患者分为高通量透析组26例、常规透析组20例和血液灌流组19例。分别于治疗前、治疗6个月后检测患者透析前血清肌酐(Scr)、尿素氮(BUN)、电解质6项、β_2微球蛋白(β_2-MG)、血清白蛋白(ALB)、血红蛋白(Hb)、总蛋白(TP)、血清磷(PO_4^(-3))和全段甲状旁腺激素(iPTH),观察患者并发症发生率。结果高通量组终末期肾衰竭患者治疗后β_2-MG、iPTH、Hb、TP、PO_4^(-3)和ALB指标均优于其他两组,差异有统计学意义(P<0.05)。高通量血液透析组患者心力衰竭、心率失常和血压异常并发症均低于常规透析组和血液灌流组,其总并发症例数的差异有统计学意义(P<0.05)。结论采用高通量血液透析治疗终末期肾衰竭患者,对患者的血液内有害物质的清除能力、营养状况的改善以及并发症发生率的控制较常规透析有明显的提升。Objective To analyze the effect of high-flux hemodialysis in the treatment of patients with end-stage renal failure. Methods A total of 65 patients with highflux hemodialysis which from inpatient were divided into high-flux hemodialysis group（26 cases）, conventional hemodialysis group（20 cases） and hemoperfusion group（19 cases）. After 6-month treatment, biochemical indicators, such as serum creatinine（Scr）, blood urea nitrogen（BUN）, β2-microglobulin（β2-MG）, albumin（ALB）, hemoglobin（Hb）, total protein（TP）, iPTH, serum phosphorus（PO4^（-3）） and complication were measured. Results The biochemical indicators of high-flux hemodialysis group, including β2-MG, ALB, Hb, TP, PO4^（-3） and iPTH were improved better after treatment than those in conventional hemodialysis group and hemoperfusion group. There were significant differences in highflux hemodialysis group and other two group（P〈0.05）. Besides, compared with conventional hemodialysis group and hemoperfusion group, high-flux hemodialysis group had lower complication rates, including heart failure, arrhythmias and abnormal blood pressure. There were significant differences in total complication cases（P 〈0.05）. Conclusion For patients with end-stage renal failure, it could improve the blood of harmful substances removal efficiency, and complication rate by high-flux hemodialysis treatment.

关 键 词：高通量血液透析 终末期肾衰竭 疗效 

分 类 号：R692.5[医药卫生—泌尿科学]